NCT03575819 - A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 4, 2019

Primary Completion Date

November 16, 2023

Study Completion Date

November 22, 2023

Conditions

Prostate Cancer Metastatic

Interventions

DRUG

FOR46

FOR46 is an intravenously (IV) administered antibody-drug conjugate (ADC) directed against CD46

Trial Locations (5)

Karmanos Cancer Institute, Detroit

Northwestern University, Chicago

UCLA Institute of Urologic Oncology, Los Angeles

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco

OHSU Knight Cancer Institute, Portland